News
CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US
We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in
Remarkable Progress in Clinical Trials: CBT-009 and CBT-004
We are proud to announce that CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA
Seeing Life Better Through Medicine
Imagine a world where everyone can experience the joy and beauty of clear vision. At Cloudbreak, our mission is centered around the belief that vision
Cloudbreak: A Clinical-Stage Company Dedicated to Improving Vision Health
Perhaps you are unfamiliar with us and unsure of what motivates us to become a mission-driven company. Today, we are excited to share our story
Cloudbreak Pharma Named a Potential Unicorn for 2023
On June 20th, 2023, Greatwall Strategy Consultants (GEI) released the “2023 China Potential Unicorns Research Report”. Cloudbreak Pharma is honoured to be named one
Cloudbreak Pharma Inc. and Centre for Eye and Vision Research Ltd. sign a memorandum of understanding for strategic cooperation in Hong Kong
On May 17th, Cloudbreak Pharma Inc. (Cloudbreak) and Centre for Eye and Vision Research Ltd. (CEVR) signed a memorandum of understanding for strategic cooperation at